Breathe Biologics
is advancing a patented clinically validated regenerative immunomodulatory platform designed to address severe pulmonary disease through immune modulation, tissue repair, and scalable cell therapy manufacturing—creating a potential foundation for the future of regenerative pulmonary medicine
COPD is a consistently progressive, ultimately fatal disease.
15.7
million Americans (6.4%) reported that they have been diagnosed with COPD
50%
of adults with low pulmonary function were not aware that they had COPD
3.23
million deaths worldwide in 2019. COPD is the third leading cause of death worldwide
90%
of COPD deaths in those under 70 years of age occur in low- and middle-income countries
7th
leading cause of poor health worldwide is COPD
70%
of COPD is smoking related in high-income countries
